A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
about
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sicknessThe anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisThe Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi InfectionNitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsA new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imagingThe crystal structure of an oligo(U):pre-mRNA duplex from a trypanosome RNA editing substrateTrypanosoma cruzi trans-Sialidase in Complex with a Neutralizing Antibody: Structure/Function Studies towards the Rational Design of InhibitorsNew Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid ParasitesComputational identification of uncharacterized cruzain binding sitesThe susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposingIn vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form--DB1965--against Trypanosoma cruzi infectionBenznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomicsComputational studies on sirtuins from Trypanosoma cruzi: structures, conformations and interactions with phytochemicalsThe Trypanosoma cruzi vitamin C dependent peroxidase confers protection against oxidative stress but is not a determinant of virulenceAntiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug RepositioningTrypanothione reductase: a target protein for a combined in vitro and in silico screening approachIdentification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in LeishmaniaQuantitative Laser Biospeckle Method for the Evaluation of the Activity of Trypanosoma cruzi Using VDRL Plates and Digital AnalysisDrug resistance in eukaryotic microorganisms.Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases).Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6.Evaluation of high efficiency gene knockout strategies for Trypanosoma cruziExploiting the drug-activating properties of a novel trypanosomal nitroreductase.Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.Regulation of CD8+ T cell responses to infection with parasitic protozoa.Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formationNovel cruzain inhibitors for the treatment of Chagas' disease.Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.Evaluating 5-nitrofurans as trypanocidal agents.Genetic dissection of drug resistance in trypanosomesHigh-throughput decoding of drug targets and drug resistance mechanisms in African trypanosomes.An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugsStructural modelling and comparative analysis of homologous, analogous and specific proteins from Trypanosoma cruzi versus Homo sapiens: putative drug targets for chagas' disease treatment.Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugsPlasmid vectors and molecular building blocks for the development of genetic manipulation tools for Trypanosoma cruzi
P2860
Q21144517-2FADFE28-CC7A-45D7-A762-A2ED7C7913A2Q24633734-204CDC83-4604-472B-A23E-E034E78F64D9Q26829884-C6F67034-7164-4644-8BBE-1295D4FDA9A9Q26863285-70778C04-EAAB-4672-92F6-533EE85A440CQ27011506-A8DBE238-D5CB-49B7-90B4-C1F5216FB1DFQ27672489-E019346A-E14D-4F90-AD55-433200C4352BQ27676712-DBBFCE46-A195-448C-88AC-9002B61BCC67Q28068159-CC17A303-2EC0-4E32-9C38-3EFB37F28CA7Q28473888-D1D698E8-94A9-4D00-A9B8-319BB8C44FB8Q28476644-77D88CE9-1A5C-49C2-8EFB-A5B8441B7019Q28479017-49D816FE-2C3C-456C-8479-89F1C7E78B3BQ28539047-E6C67976-9E64-403B-BA91-01B109B6A947Q28539769-6536C1D1-C1EE-4487-BA55-93604F5535D2Q28546218-76398F23-066A-4568-ABDC-92EE67FAB06AQ28547217-EA9C2486-AF25-4DB8-BD2A-AB4A0C4ACEDAQ28547882-2B6945E9-A3C0-44AB-A956-A8FDA8E014D8Q28551393-1A572ED4-6566-4089-876D-ABCDEE10BE68Q28553178-09C5009D-B90C-4ED3-8476-E86D1E3C8864Q28554785-7702F702-D8B6-428A-BC7B-97C541DC11C2Q30248243-75B8D169-AEDD-4EFD-91FD-3911CE1B0808Q30439011-E4B1D0C7-F8FD-4230-A4AE-B419AD04872AQ30992269-B48A0491-D124-49F1-A188-6015CBE32340Q33443498-C68D72CD-572C-460C-AC16-16E8849D43F5Q33520395-30059248-1D90-4FC9-A25F-8E8D2E5D362EQ33653056-03145A29-9B8E-487E-B121-89798BF22267Q33681753-D8853A32-9F40-4404-B07F-76D2ACBE007EQ33733004-4CF0F0C7-8D99-4D8E-95F5-DA65EEF80219Q34105267-896BB649-0434-42AB-8DF4-8912BEFF44A0Q34108177-D1BD656E-EE09-4369-BC8F-9AD9A598F01DQ34113517-62DE51DD-4222-464D-870F-527FB70F62D3Q34228648-3C1E7885-8316-4080-A6B5-068647DE8B5EQ34276214-717AF466-152E-4396-92E7-354F52A2805FQ34403287-0D9DBF77-DCB7-4234-9666-384760A6EBF3Q34555495-A232F867-A531-48BD-801C-C905053980AFQ34647009-3BC73FD4-EF56-4A46-BFFB-FFAB31C8D080Q34657072-7A5B2945-297F-4765-B7F8-7C919F33BE83Q34942136-E714FCF7-AA9B-4F8B-8BE9-D2986E21B14FQ34968549-47B17CD6-17A5-4B9A-A0A9-B0950C595ED6Q35027309-3A2FA2F6-D93E-43E7-A8C9-391E437697B7Q35036992-E6384B67-E2D9-4AEB-8B11-A2E2AA5ABFF1
P2860
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@ast
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@en
type
label
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@ast
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@en
prefLabel
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@ast
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@en
P2093
P2860
P50
P921
P356
P1476
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
@en
P2093
Ian Cheeseman
John M Kelly
Shane R Wilkinson
P2860
P304
P356
10.1073/PNAS.0711014105
P407
P5008
P577
2008-03-26T00:00:00Z